CD40 and head and neck cancer: The HARE-40 is a phase I/II trial of a mRNA-based vaccine against the E6 and E7 oncoproteins in combination with anti-CD40 antibody in patients with HPV 16+ head and neck cancers (NCT03418480) that is now active.